Nova Patents
EP0444482A2

Oxetanones.

Abstract

Es werden neue die Pankreaslipase hemmende Oxetanone der Formel worin Q, R¹ und R² die in der Beschreibung angegebene Bedeutung haben, offenbart, die ausgehend von entsprechenden β-Hydroxycarbonsäuren hergestellt werden.

EP0444482A2, drawing sheet 1
Sheet 1 of 27

Term

Term ended

Projected expiry passed 15 February 2011, 15.6 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

13 claims: 3 independent, 10 dependent

  1. 1
    Oxetanones of the formula wherein Q is a group of the formula         (R³, R⁴) NCO (X) n-CO-Q1         (R3, R⁴) NCO-X'- Q2 or is and R¹ and R² with 1 to 3 halogen atoms substituted alkyl with up to 18 C atoms or optionally interrupted by a 1,4-arylene group, optionally substituted by an aryl group in the ω-position and optionally substituted by an aryl-C₁₋₄-alkyl group Are alkenyl, alkynyl or alkadienyl groups with up to 20 C atoms, where R¹ can be interrupted by an O or S atom or by a sulfinyl or sulfonyl group other than the α position to an unsaturated C atom, or R¹ can be an aryl-NH- or aryl-C₁₋₄- group alkyl-OCONH-, R³ and R⁴ are hydrogen or C₁₋₄-alkyl or, together with the N atom to which they are attached, a saturated 3 to 6-membered, optionally an O or S atom in a position other than the α-position to form the ring containing the N atom, n is the number 1 or 0, X is an alkylene group which is optionally interrupted by an O or S atom or by a sulfinyl or sulfonyl group and which contains up to 6 carbon atoms and optionally by a hydroxy, mercapto, aryl, aryloxy, arylthio, aryl -C₁₋₄-alkyl, aryl-C₁₋₄-alkoxy-, aryl-C₁₋₄-alkylthio, aryl-C₁₋₄-alkylidene, C₃₋₇-cycloalkylidene or C₁₋₆-alkylidene group or by one or two C₁₋₆ alkyl, C₁₋₆ alkoxy or C₁₋₆ alkylthio groups is substituted, where two C₁₋₆-alkyl, C₁₋₆-alkyl or C₁₋₆-alkylthio groups bonded to the same carbon atom or to two adjacent carbon atoms can form an optionally monounsaturated 3 to 7-membered ring and an optionally present one Hydroxy or mercapto group or an unsaturated carbon atom which may be present must be in a position other than the α position to an O or S atom which may be present or a sulfinyl or sulfonyl group which may be present, or X is a group of the formula         = CHN (R, R O ) or -CHN (R, R O ) CH₂- R and R O Hydrogen, C₁₋₄-alkyl- C₁₋₄-alkyl (CO or OCO) -, aryl, aryl (CO or OCO) -, aryl-C₁₋₄-alkyl or aryl-C₁₋₄-alkyl (CO or OCO) - are and X 'is an alkylene group containing up to 6 C atoms, which is substituted by a C₁₋₄ alkoxy, aryl, aryloxy, arylthio, aryl C₁₋₄ alkyl, aryl C₁₋₄ alkoxy or Aryl-C₁₋₄-alkylthio group or by one or two C₁₋₆-alkyl group (s) may be substituted, wherein two C₁₋₆-alkyl groups bonded to adjacent C atoms can form a 3- to 7-membered ring.
  2. 12
    Medicament containing an oxetanone according to one of claims 1-9 and a therapeutically inert carrier material.
  3. 13
    Use of an oxetanone according to any one of claims 1-9 in the manufacture of a medicament for combating or preventing obesity, hyperlipemia, atherosclerosis and arteriosclerosis.